Association between CYP2E1 genetic polymorphisms and urinary cancer risk: a meta-analysis
PDF | HTML | How to cite
Metrics: PDF 1460 views | HTML 1778 views | ?
Zhiqing Fang1, Yun Wu2 and Ning Zhang2
1Department of Urology, Qilu Hospital, Shandong University, Jinan, Shandong, China
2Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, China
Ning Zhang, email: [email protected]
Keywords: cytochrome P4502E1, CYP2E1, polymorphism, urinary cancer, meta-analysis
Received: October 25, 2016 Accepted: August 29, 2017 Published: September 18, 2017
Objective: Studies investigating the contribution of Cytochrome P4502E1 (CYP2E1) polymorphisms to the etiology of urinary cancer draw inconsistent conclusions. Thus, we performed a meta-analysis to evaluate the association between CYP2E1 Rsa I/Pst I and Dra I polymorphisms and urinary cancer susceptibility.
Materials and Methods: Meta-analysis based on the eligible case-control studies that assess the association of CYP2E1 Rsa I/Pst I and Dra I polymorphisms with urinary cancer was conducted. Subgroup analyses based on ethnicity and cancer type were also carried out. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the strength of the associations between the two polymorphisms. Funnel plot and Begg’s test were used for publication bias diagnosis.
Results: We found decreased urinary cancer risk among subjects carrying CYP2E1 RsaI/PstI c1c2 + c2c2 genotype and c2 allele (OR = 0.73, 95% CI = 0.68–0.79 and OR = 0.79, 95% CI = 0.74–0.85, respectively), with 3,301 cases and 3,786 controls from 14 studies. We also observed a significant difference in c1c2 + c2c2 vs. c1c1 and c2 vs. c1 among Asians (OR = 0.68, 95% CI = 0.60–0.78 and OR = 0.75, 95% CI = 0.66–0.85, respectively). However, the meta-analysis based on 5 eligible studies showed no significant association between CYP2E1 Dra I polymorphism and urinary cancer susceptibility in either dominant model or the allele model.
Conclusions: Our meta-analysis concluded that CYP2E1 Rsa I/Pst I polymorphism correlates with urinary cancers risk in Asian population; while CYP2E1 Dra I polymorphism might be not significantly associated with the urinary cancer risks. Large and well-designed studies are needed to confirm these results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.